ConductScience.org, home

Paper7907950

Pharmacokinetics and metabolism of Taxotere (docetaxel).

Bruno R and 1 other. Cancer Surv, 1993. Cited by 84 papers, by iCite.

Cite this record

ConductScience Library. Pharmacokinetics and metabolism of Taxotere (docetaxel). Papers, record 7907950. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7907950

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetics and metabolism of Taxotere (docetaxel).
PubMed
Journal
Cancer Surv
PubMed
Year
1993
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
84
iCite
Relative citation ratio, by iCite
2.59
iCite
Revised in PubMed
2018-11-30
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bruno RR
2Sanderink GJG J

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, PhytogenicMajor topic
NeoplasmsMajor topic
PaclitaxelMajor topic
TaxoidsMajor topic
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Docetaxel
Humans

Source PubMed

Download CSV of topics

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 84 citations.

PMIDTitleJournalYearIn PapersSource
42882832Neoadjuvant Advantage, Adjuvant Challenge: Clinical Evidence and Hypothetical Biological Mechanisms Behind Divergent Tolerability.Cancers (Basel)2026https://conductscience.org/library/papers/42882832PubMed
38554227Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions.J Pharmacokinet Pharmacodyn2024https://conductscience.org/library/papers/38554227PubMed
38093346Dynamic altruistic cooperation within breast tumors.Mol Cancer2023https://conductscience.org/library/papers/38093346PubMed
32969563Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.BJU Int2021https://conductscience.org/library/papers/32969563PubMed
29977602Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer.NPJ Syst Biol Appl2018https://conductscience.org/library/papers/29977602PubMed
25728850Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.Cancer Sci2015https://conductscience.org/library/papers/25728850PubMed
24639951In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.Front Oncol2014https://conductscience.org/library/papers/24639951PubMed
24442774Efficacy, pharmacokinetics, and biodistribution of thermosensitive chitosan/β-glycerophosphate hydrogel loaded with docetaxel.AAPS PharmSciTech2014https://conductscience.org/library/papers/24442774PubMed
23616082Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice.J Pharmacokinet Pharmacodyn2013https://conductscience.org/library/papers/23616082PubMed
21692829Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.Br J Clin Pharmacol2011https://conductscience.org/library/papers/21692829PubMed
20959830Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.Br J Cancer2010https://conductscience.org/library/papers/20959830PubMed
20399458A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.J Urol2010https://conductscience.org/library/papers/20399458PubMed
18611060Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.Clin Pharmacokinet2008https://conductscience.org/library/papers/18611060PubMed
15122076Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC).Invest New Drugs2004https://conductscience.org/library/papers/15122076PubMed
10933515Docetaxel: a review of its use in non-small cell lung cancer.Drugs Aging2000https://conductscience.org/library/papers/10933515PubMed
10883663A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.Br J Cancer2000https://conductscience.org/library/papers/10883663PubMed
10803455Adaptive control methods for the dose individualisation of anticancer agents.Clin Pharmacokinet2000https://conductscience.org/library/papers/10803455PubMed
10776837Docetaxel: an update of its use in advanced breast cancer.Drugs2000https://conductscience.org/library/papers/10776837PubMed
9878990Practical treatment guide for dose individualisation in cancer chemotherapy.Drugs1998https://conductscience.org/library/papers/9878990PubMed
8913835Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein.Invest New Drugs1996https://conductscience.org/library/papers/8913835PubMed

See all 23 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7907950

GET https://conductscience.org/api/papers/v1/7907950/cited_by?page=2